MethylphenIdate for Fatigue in Haematological Cancer
Status:
Unknown status
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Cancer related fatigue (CRF) is the most debilitating problem for patients with
haematological cancer. CRF severely reduces quality of life (QoL), functional capacity,
impacts health behavior, recovery and furthermore no approved treatment exists. In solid
cancer methylphenidat (MTP) has been suggested to improve CRF, however patients with
haematological cancer has not been studied. The current randomized placebo controlled study
includes a variety of severely fatigued haematological cancer patients from seven Danish
departments. It aims at revealing whether MTP can improve CRF, functional capacity and QoL
thereby hopefully providing improvement and treatment options in this field where
improvements are requested the most by patients. Patients are randomized to treatment with
MTP or placebo week 1-6 followed by "wash-out" and cross-over - placebo to MTP or vice versa
- during week 8-13. End-points will be patient reported fatigue, as well as improvements in
active hours, functional capacity, and QoL.